<DOC>
	<DOCNO>NCT02178540</DOCNO>
	<brief_summary>The purpose actual use human factor ( HF ) study validate approve US TOBI Podhaler Instructions Use ( IFU ) , establish IFU effectively communicate information necessary achieve safe effective use Podhaler device .</brief_summary>
	<brief_title>Study Validate Instructions Use TOBI® Podhaler™ Cystic Fibrosis Patients</brief_title>
	<detailed_description>The objective HF study determine whether cystic fibrosis patient US , representative potential TOBI Podhaler user , understand follow approve IFU extent approve IFU support safe effective use Podhaler device . This study 'actual use ' study , patient inhale content placebo capsule Podhaler device . Due use placebo capsule , study consider clinical study conduct accordingly . The study therefore human factor observational use study conduct within clinical study . It open label , unblinded , non-randomized study consist two visit . At visit 2 patient eligible participate human factor assessment determine whether patient understands IFU content demonstrate safe effective use Podhaler device .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Male female subject age 6 year old screening Confirmed diagnosis CF Pulmonary function FEV1 value least 25 % normal predicted value Must physically cognitively able read , alone assistance caregiver Subjects currently enrol study consider observational noninvestigational study . Subjects use Podhaler device previously Hemoptysis 60mL time within 30 day prior study drug administration History hypersensitivity inhale dry powder Signs symptom acute pulmonary disease , e.g. , pneumonia , pneumothorax</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Human factor , TOBI® Podhaler™ , Instructions For use , IFU , CF patient</keyword>
</DOC>